Canaccord raised the firm’s price target on Privia Health (PRVA) to $34 from $32 and keeps a Buy rating on the shares. The firm said its thesis on the copany is playing out as the Q3 beat was strong across the board and management noted that 3Q capitated results would likely be the high-water mark for 2025 as there was retroactive timing of data that contributed to the strength.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: